therapy for Waldenstrom macroglobulinemia对于常规治疗原发性巨球蛋白血症ppt课件.ppt

下载文档 降价啦

8
0
约2.44千字
约 42页
2018-08-06 发布于贵州
举报
版权申诉
保障服务

therapy for Waldenstrom macroglobulinemia对于常规治疗原发性巨球蛋白血症ppt课件.ppt

1、本文档共42页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

therapy for Waldenstrom macroglobulinemia对于常规治疗原发性巨球蛋白血症ppt课件

Waldenstr?m macroglobulinemia;Topics to be covered - ;What is Waldenstr?m macroglobulinemia?;Waldenstr?m macroglobulinemia“A disease with two problems”;Lymphoplasmacytic infiltrate (usually intertrabecular) Immunophenotype - surface IgM+, CD19+, CD20+, CD79a+ and PAX5+. CD5?, CD10?, CD23?. exclude CLL and mantle cell lymphoma del(6)(q21) is the most common genetic abnormality seen;Waldenstr?m macroglobulinemia Monoclonal IgM;MYD88 Mutations in Waldenstr?m macroglobulinemia;Waldenstr?m macroglobulinemia – presenting symptoms;Hyperviscosity due to Waldenstr?m macroglobulinemia;IgM deposition due to Waldenstr?m macroglobulinemia;Autoimmune hemolysis secondary to Waldenstr?m macroglobulinemia ;Diagnostic Criteria for Waldenstr?m macroglobulinemia ;Time to developing WM and Survival in patients with Indolent WM or IgM MGUS;Risk of progression from IgM MGUS to WM or another B-cell malignancy;Survival of 587 symptomatic patients with Waldenstr?m macroglobulinemia ;Who needs treatment?;Patient 1;Patient 2;Many treatment options;Does everyone need treatment at diagnosis?;García-Sanz et al. Brit J Haematol. 115: 575-582, 2001;What clinical findings suggest that treatment should be started?;Before starting therapy – Does the patient have hyperviscosity and do they need plasmapheresis?;Plasmapheresis for Waldenstr?ms patients with hyperviscosity;Before plasmapheresis - optic disc edema (arrowheads), central retinal hemorrhages (bold arrows), and venous “sausaging” (thin arrows). ;Initial treatment for untreated symptomatic WM patients;Common Treatments used as initial therapy for WM ;Purine analogue based combinations – FCR/FR;Leleu X et al. JCO 2009;27:250-255;Alkylating agent based combinations – R-CHOP;Alkylating agent based combinations – DRC;Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstr?ms macroglobulinemia. ;Alkylating agent based combinations – R-Bendamustine;Bendamustine plus rituximab compared with R-CHOP in WM patients;Bortezomib based